Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

FDA Speeds Reviews in 2026; AI and Old GMP Failures Put Approvals at Risk

Pharmaceutical manufacturing is entering a faster regulatory era. FDA is testing accelerated review models, companies are investing in artificial intelligence, and manufacturers are reconsidering where critical products should be produced. However, FDA’s latest quality data reveal an uncomfortable reality: faster
  • News
FDA Speeds Reviews in 2026; AI and Old GMP Failures Put Approvals at Risk

India’s Drug Innovation Surges; BCG Warns 90-Day Trial Delays Could Stall Scale-Up

India’s life sciences sector has reached a critical turning point as local companies move beyond generics and develop novel drugs, CAR-T therapies, and AI-discovered molecules. However, a new report from Boston Consulting Group and HealthKois warns that weak clinical execution,
  • News
India’s Drug Innovation Surges; BCG Warns 90-Day Trial Delays Could Stall Scale-Up

Novartis Wins Full FDA Approval for Fabhalta; 2-Year IgAN Data Confirm Slower Kidney Decline

Novartis has secured full US FDA approval for Fabhalta in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. The regulator converted the drug’s accelerated approval into a traditional approval after two-year phase 3 data showed
  • News
Novartis Wins Full FDA Approval for Fabhalta; 2-Year IgAN Data Confirm Slower Kidney Decline

EMA–EISMEA Formalize 2026–2027 Program; Small Biotechs Face Late CMC Rework

The European Medicines Agency (EMA) and the European Innovation Council and SMEs Executive Agency (EISMEA) strengthened their cooperation on July 15, 2026. Their new 2026–2027 work program will help European health innovators understand regulatory expectations earlier. The initiative matters because
  • News
EMA–EISMEA Formalize 2026–2027 Program; Small Biotechs Face Late CMC Rework

Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen has revealed mixed CELIA Phase II trial data for diranersen at AAIC 2026. The lowest 60 mg dose slowed clinical decline more than either 115 mg arm, although CELIA aimed to show greater benefit at higher doses. Consequently, the
  • News
Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen’s Lowest Dose Wins; BIIB080’s Failed Dose Response Raises Phase 3 Risk

Biogen has reported detailed results from the Phase 2 CELIA trial for diranersen (BIIB080) in early Alzheimer’s disease. The drug reduced tau and slowed cognitive decline across several measures. However, the lowest dose produced the strongest effect, so the study
  • News
Biogen’s Lowest Dose Wins; BIIB080’s Failed Dose Response Raises Phase 3 Risk

Functional Unblinding Threatens Psychedelic Trial Credibility; FDA Guidance Could Force Phase III Redesigns

The US Food and Drug Administration (FDA) has finalized its guidance for clinical trials involving psychedelic drugs. The document covers trial design, participant safety, abuse potential, data collection, and preclinical work. The FDA and the Department of Health and Human
  • News
Functional Unblinding Threatens Psychedelic Trial Credibility; FDA Guidance Could Force Phase III Redesigns

Redi Health Reaches 9 of Top 10 Pharma Manufacturers; GxP Questions Follow

Nine of the world’s top 10 pharmaceutical manufacturers now use Redi Health to modernize patient support, according to a sponsored report published on July 13, 2026. The shift reflects demand for faster, more personalized patient experiences. However, it also places
  • News
Redi Health Reaches 9 of Top 10 Pharma Manufacturers; GxP Questions Follow

FDA Rejected Utebzi; Now Spero Strikes a $1.1B Innovent Deal

Spero Therapeutics is shifting from antibiotics to immune and inflammatory diseases through a licensing agreement with Innovent Biologics worth up to $1.1 billion. The company will develop SP001, a CD40L antibody, outside China. At the same time, Spero secured $105
  • News
FDA Rejected Utebzi; Now Spero Strikes a $1.1B Innovent Deal

Biotech Hubs Are Expanding; Why GMP Complexity Is Rising Across Pharma

Emerging Biotech Hubs across North America, Europe, and Asia are attracting new pharmaceutical investments, research facilities, and global talent in 2026. While this expansion reflects strong industry growth, it also introduces new GMP Compliance challenges, validation demands, and Quality Systems
  • News
Biotech Hubs Are Expanding; Why GMP Complexity Is Rising Across Pharma